Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA)
recently approved ISENTRESS for oral suspension, a new
pediatric formulation of Mercks integrase inhibitor. With this
approval, ISENTRESS is now indicated in combination with other
antiretroviral (ARV) agents for the treatment of HIV-1 infection in
patients four weeks of age and older.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more